NcXHF

APOLO, VOGELZANG, AND THEODORESCU
Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol.
2010;28 (suppl; abstr LBA4518).
77. Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred
chemotherapy after radical cystectomy in patients with pT3-pT4 or N
M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup,
open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:76-86.
78. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.
Nat Rev Cancer. 2012;12:252-264.
79. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab
in patients with metastatic melanoma. N Engl J Med. 2010;363:
711-723.
80. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance
and immunity. Annu Rev Immunol. 2008;26:677-704.
81. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed
cell death 1 and its ligands in regulating autoimmunity and infection.
Nat Immunol. 2007;8:239-245.
82. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and
autoimmunity. Immunol Rev. 2010;236:219-242.
83. Nakanishi J, Wada Y, Matsumoto K, et al. Overexpression of B7-H1
(PD-L1) signifıcantly associates with tumor grade and postoperative
prognosis in human urothelial cancers. Cancer Immunol Immunother.
2007;56:1173-1182.
84. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial
carcinoma of the bladder and BCG-induced granulomata: associations
with localized stage progression. Cancer. 2007;109:1499-1505.
85. Wang Y, Zhuang Q, Zhou S, et al. Costimulatory molecule B7-H1 on the
immune escape of bladder cancer and its clinical signifıcance. J Huazhong
Univ Sci Technolog Med Sci. 2009;29:77-79.
86. Xylinas E, Robinson BD, Kluth LA, et al. Association of T-cell coregulatory
protein expression with clinical outcomes following radical
cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol.
2014;40:121-127.
87. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:
2443-2454.
88. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-
PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;
366:2455-2465.
89. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment
leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:
558-562.
90. Plimack ER, Gupta S, Bellmunt J, et al. A phase 1b study of pembrolizumab
(Pembro; MK-3475) in patients (Pts) with advanced urothelial
tract cancer. Ann Oncol. 2014;25:1-41 (suppl; abstr LBA23).
112 2015 ASCO EDUCATIONAL BOOK | asco.org/edbook